Platform

Quorum Innovations has built an exciting and broad portfolio of active microbiome biotherapeutics through the real-world application of translational medicine.  By viewing human health and disease through the lens of the human microbiome, the physician-founders undertook the development of microbiome biotherapeutics for clinical entities that are only now beginning to be re-interpreted as dysbiotic states.  The Company physician-founders input clinical relevancy into the research and biotherapeutic discovery process, deriving biotherapeutics from the inherently beneficial human microbiome and working from human target-organ studies.  Combining their early recognition of the many potential clinical applications of the human microbiome with a translational medicine approach has resulted in Quorum Innovations’  discovery of several Probiomic^TM biotherapeutics, currently under active development for the treatment of multiple clinical entities ranging from chronic skin inflammation,  chronic inflammation of the upper respiratory and digestive tracts.